PTPN1 and type 2 diabetes mellitus: Several cellular and metabolic targets are involved to ameliorate T2D complications, such as, α-glucosidase and protein tyrosine phosphatase 1 beta (PTP1B) inhibition, correction of abnormal insulin signalling, promotion of the action of insulin on its target tissues, including antioxidative and anti-inflammatory action [3].